Auflistung Nach Schlagwort "Programmed Cell Death 1 Receptor"

Anzeige der Dokumente 1-3 von 3

Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures

Padhan K., Moysi E., Noto A., Chassiakos A., Ghneim K., Perra M.M., Shah S., Papaioannou V., Fabozzi G., Ambrozak D.R., Poultsidi A., Ioannou M., Fenwick C., Darko S., Douek D.C., Sekaly R.-P., Pantaleo G., Koup R.A., Petrovas C. (2021)

The development of follicular helper CD4 T (TFH) cells is a dynamic process resulting in a heterogenous pool of TFH subsets. However, the cellular and molecular determinants of this heterogeneity and the possible mechanistic ...
Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient

Eleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I. (2021)

Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the ...
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer

Tsoukalas N., Kiakou M., Tsapakidis K., Tolia M., Aravantinou-Fatorou E., Baxevanos P., Kyrgias G., Theocharis S. (2019)

The integration of immunotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC) has revolutionized the approach of the prevalent type of lung cancer. Although PD-1 and its ligands (PD-L1 and PD-L2) are ...